Published in PLoS One on November 16, 2012
Osteoclasts: more than 'bone eaters'. Trends Mol Med (2014) 1.17
Contributions of the host microenvironment to cancer-induced bone disease. Cancer Res (2014) 1.07
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front Oncol (2014) 1.04
Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood (2015) 1.04
Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases. Cancer Metastasis Rev (2014) 1.00
Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. Front Oncol (2014) 0.94
Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis. Cancer Res (2013) 0.93
Osteoclasts-Key Players in Skeletal Health and Disease. Microbiol Spectr (2016) 0.88
Bone and the innate immune system. Curr Osteoporos Rep (2014) 0.83
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood (2016) 0.83
Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells. Oncotarget (2015) 0.82
Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). Oncotarget (2016) 0.81
Bone-immune cell crosstalk: bone diseases. J Immunol Res (2015) 0.80
Immune regulation of bone metastasis. Bonekey Rep (2014) 0.80
Human osteoclasts are inducible immunosuppressive cells in response to T cell-derived IFN-γ and CD40 ligand in vitro. J Bone Miner Res (2014) 0.78
Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents. J Nucl Med (2016) 0.78
Dissecting the role of bone marrow stromal cells on bone metastases. Biomed Res Int (2014) 0.78
Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease. Oncoimmunology (2013) 0.78
Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. Oncotarget (2016) 0.76
Immunotherapy strategies for multiple myeloma: the present and the future. Immunotherapy (2013) 0.76
The Impact of Immune System in Regulating Bone Metastasis Formation by Osteotropic Tumors. J Immunol Res (2015) 0.76
Location of tumor affects local and distant immune cell type and number. Immun Inflamm Dis (2017) 0.75
The role of MDSCs in bone metastasis and cancer-related osteolysis. Bonekey Rep (2013) 0.75
One microenvironment does not fit all: heterogeneity beyond cancer cells. Cancer Metastasis Rev (2016) 0.75
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities. J Mol Med (Berl) (2015) 0.75
The Phenotype and Function of Myeloid-derived Suppressor Cells Induced by Porphyromonas gingivalis Infection. Infect Immun (2017) 0.75
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem (1996) 8.08
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med (2007) 5.48
Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol (2007) 4.65
Multiple myeloma. Lancet (2009) 4.60
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res (2004) 3.94
Preparing the "soil": the premetastatic niche. Cancer Res (2006) 2.92
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res (2009) 2.90
Multiple myeloma. N Engl J Med (1997) 1.94
Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev (2006) 1.89
Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res (1994) 1.84
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood (2004) 1.78
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood (2007) 1.75
Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One (2009) 1.72
Niche-to-niche migration of bone-marrow-derived cells. Trends Mol Med (2007) 1.72
Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol (2008) 1.69
The pathogenesis of the bone disease of multiple myeloma. Bone (2008) 1.51
Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol (1999) 1.48
Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche. Breast Dis (2007) 1.47
Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer (2005) 1.46
Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood (1999) 1.40
Molecular mechanisms of action of bisphosphonates. Bone (1999) 1.33
Human osteoclasts derive from CD14-positive monocytes. Br J Haematol (1999) 1.30
Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res (2003) 1.28
Prenylation of Ras proteins is required for efficient hSOS1-promoted guanine nucleotide exchange. J Biol Chem (1994) 1.24
HERG K+ channels activation during beta(1) integrin-mediated adhesion to fibronectin induces an up-regulation of alpha(v)beta(3) integrin in the preosteoclastic leukemia cell line FLG 29.1. J Biol Chem (2000) 1.09
miR-223 suppresses differentiation of tumor-induced CD11b⁺ Gr1⁺ myeloid-derived suppressor cells from bone marrow cells. Int J Cancer (2011) 1.08
A murine model of myeloma that allows genetic manipulation of the host microenvironment. Dis Model Mech (2009) 1.04
Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res (1999) 1.04
Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. Int J Cancer (2006) 0.99
Expression of the calcitonin receptor, calcitonin receptor-like receptor, and receptor activity modifying proteins during osteoclast differentiation. J Cell Biochem (2008) 0.93
The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane. Eur J Haematol (2005) 0.92
First thalidomide clinical trial in multiple myeloma: a decade. Blood (2008) 0.90
Functional changes in myeloid-derived suppressor cells (MDSCs) during tumor growth: FKBP51 contributes to the regulation of the immunosuppressive function of MDSCs. J Immunol (2012) 0.88
Multiple myeloma and related disorders. Lessons from an animal model. Pathol Biol (Paris) (1999) 0.86
The birth of the osteoclast. Ann N Y Acad Sci (2010) 0.79
Bone morphogenetic proteins. Growth Factors (2004) 8.61
Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature (2005) 6.43
Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell (2004) 5.80
A twist code determines the onset of osteoblast differentiation. Dev Cell (2004) 5.40
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem (2005) 5.33
Deletion of dentin matrix protein-1 leads to a partial failure of maturation of predentin into dentin, hypomineralization, and expanded cavities of pulp and root canal during postnatal tooth development. J Biol Chem (2004) 3.21
Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol (2012) 2.58
Dentin matrix protein 1, a target molecule for Cbfa1 in bone, is a unique bone marker gene. J Bone Miner Res (2002) 2.36
E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem (2003) 2.34
Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet (2005) 2.10
Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem (2002) 1.99
Cooperative interactions between activating transcription factor 4 and Runx2/Cbfa1 stimulate osteoblast-specific osteocalcin gene expression. J Biol Chem (2005) 1.91
Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood (2011) 1.88
Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation. J Cell Biol (2002) 1.88
Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res (2006) 1.82
Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo. J Biol Chem (2003) 1.81
Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol (2011) 1.76
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood (2007) 1.75
Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res (2012) 1.75
Transcriptional coactivation of bone-specific transcription factor Cbfa1 by TAZ. Mol Cell Biol (2003) 1.69
Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res (2012) 1.65
GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS One (2008) 1.63
The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res (2006) 1.62
Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer (2003) 1.58
Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone (2004) 1.57
TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res (2010) 1.57
Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood (2003) 1.56
Silent information regulator (Sir)T1 inhibits NF-κB signaling to maintain normal skeletal remodeling. J Bone Miner Res (2013) 1.54
Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone (2010) 1.54
Intimo-intimal intussusception of the aorta. Ann Thorac Surg (2006) 1.53
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res (2003) 1.52
The pathogenesis of the bone disease of multiple myeloma. Bone (2008) 1.51
Caspase-2 deficiency enhances aging-related traits in mice. Mech Ageing Dev (2006) 1.46
The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling. Mol Cell Biol (2006) 1.45
Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer (2010) 1.45
Model structure and control of bone remodeling: a theoretical study. Bone (2008) 1.44
NF-kappaB specifically activates BMP-2 gene expression in growth plate chondrocytes in vivo and in a chondrocyte cell line in vitro. J Biol Chem (2003) 1.35
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32
Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood (2004) 1.29
Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther (2007) 1.28
Longitudinal live animal micro-CT allows for quantitative analysis of tumor-induced bone destruction. Bone (2010) 1.26
Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction. Oncoimmunology (2012) 1.19
Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol (2007) 1.19
Eph receptors and ephrin signaling pathways: a role in bone homeostasis. Int J Med Sci (2008) 1.17
The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat (2002) 1.15
Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J Bone Miner Res (2010) 1.15
Localization of bone morphogenetic proteins (BMPs)-2, -4, and -6 within megakaryocytes and platelets. Bone (2004) 1.15
Atf4 regulates chondrocyte proliferation and differentiation during endochondral ossification by activating Ihh transcription. Development (2009) 1.15
Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest (2002) 1.12
Genetic mouse models for bone studies--strengths and limitations. Bone (2011) 1.10
Transforming growth factor β suppresses osteoblast differentiation via the vimentin activating transcription factor 4 (ATF4) axis. J Biol Chem (2012) 1.10
Inhibition of microtubule assembly in osteoblasts stimulates bone morphogenetic protein 2 expression and bone formation through transcription factor Gli2. Mol Cell Biol (2008) 1.10
Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS One (2011) 1.08
Contributions of the host microenvironment to cancer-induced bone disease. Cancer Res (2014) 1.07
Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. Hum Mol Genet (2011) 1.06
Quantitative measures of femoral fracture repair in rats derived by micro-computed tomography. J Biomech (2009) 1.05
Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. Am J Hematol (2009) 1.05
A murine model of myeloma that allows genetic manipulation of the host microenvironment. Dis Model Mech (2009) 1.04
Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone. J Bone Miner Res (2011) 1.04
Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS One (2010) 1.03
Vimentin inhibits ATF4-mediated osteocalcin transcription and osteoblast differentiation. J Biol Chem (2009) 1.02
PTH-related peptide (PTHrP) in hypercalcemia. J Am Soc Nephrol (2008) 1.02
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. Cancer (2003) 0.99
A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease. Biol Direct (2010) 0.99
Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone. PLoS One (2013) 0.99
Transcriptional regulation of BMP2 expression by the PTH-CREB signaling pathway in osteoblasts. PLoS One (2011) 0.98
Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. J Theor Biol (2009) 0.98
Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Res (2009) 0.98
Tumor-host cell interactions in the bone disease of myeloma. Bone (2010) 0.96
An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment. PLoS One (2012) 0.95
Expression and synthesis of bone morphogenetic proteins by osteoclasts: a possible path to anabolic bone remodeling. J Histochem Cytochem (2008) 0.95
Chondrocytic Atf4 regulates osteoblast differentiation and function via Ihh. Development (2011) 0.92
Bmp2 in osteoblasts of periosteum and trabecular bone links bone formation to vascularization and mesenchymal stem cells. J Cell Sci (2013) 0.92
Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis. J Bone Miner Res (2010) 0.92
β2-Adrenergic receptor signaling in osteoblasts contributes to the catabolic effect of glucocorticoids on bone. Endocrinology (2011) 0.91
Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. J Bone Miner Res (2010) 0.88
Large retrosternal goitre: a diagnostic and management dilemma. Heart Lung Circ (2006) 0.88
Intracellular trafficking and surface expression of SS-A (Ro), SS-B (La), poly(ADP-ribose) polymerase and alpha-fodrin autoantigens during apoptosis in human salivary gland cells induced by tumour necrosis factor-alpha. Arch Oral Biol (2002) 0.88
Impaired osteoblast function in GPRC6A null mice. J Bone Miner Res (2010) 0.87
Hedgehog coordination of postnatal osteoclast and osteoblast activities. Dev Cell (2008) 0.85
Occipital anaplastic oligodendroglioma with multiple organ metastases after a short clinical course: a case report and literature review. Diagn Pathol (2014) 0.85
Transdermal lovastatin enhances fracture repair in rats. J Bone Miner Res (2008) 0.85